Literature DB >> 15390298

A survey of resources and activities in the MISPHO family of institutions in Latin America: a comparison of two eras.

Alessandra Sala1, Ronald D Barr, Giuseppe Masera.   

Abstract

BACKGROUND: In developing countries, implementation of effective pediatric cancer programs can reduce the overall rate of childhood mortality. To promote this objective, Monzas International School of Pediatric Hematology-Oncology (MISPHO)--for 14 countries with limited resources in Latin America--was launched in 1996.
METHODS: A survey was conducted to evaluate the possible impact of MISPHO on the following areas: research, educational, and clinical activities, diagnostic services, transfusion medicine, supportive care, ancillary staffing complement, and parents' associations--before and after 1996.
RESULTS: No institution lost resources or activities after 1996 and there were overall gains, in particular in educational activities, diagnostic capabilities, creation of single and multiple institutional treatment protocols.
CONCLUSIONS: Although notable improvements have occurred, there are still important needs that have to be satisfied. 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15390298     DOI: 10.1002/pbc.20137

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  2 in total

1.  Addressing regional disparities in pediatric oncology: Results of a collaborative initiative across the Mexican-North American border.

Authors:  Paula Aristizabal; Spencer Fuller; Rebeca Rivera-Gomez; Mario Ornelas; Laura Nuno; Carlos Rodriguez-Galindo; Raul Ribeiro; William Roberts
Journal:  Pediatr Blood Cancer       Date:  2016-12-21       Impact factor: 3.167

2.  Development of retinoblastoma programs in Central America.

Authors:  Judith A Wilimas; Matthew W Wilson; Barrett G Haik; Margarita Barnoya; Ligia Fu; Mauricio Castellanos; Miguel Bonilla; Blanca Phillips; Eugene M Helveston; Sandra Luna-Fineman; Raul Ribeiro; Carlos Rodriguez-Galindo
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.